The Impact of Psoriasis and Metabolic Syndrome on the Systemic Inflammation and Oxidative Damage to Nucleic Acids

Table 2

The levels of calprotectin, ANGPTL8, and oxidative damage to nucleic acids in patients and controls with and without MetS.

Parameter	Q1	Median	Q3	Geometric mean	Min	Max	Significance of the differences
Calprotectin (pg/mL)
Patients No-MetS	4298.0	4746.0	7233.8	5746.0	1976.0	12538.0	NS
Patients MetS	4020.3	5612.5	8590.8	6310.3	1360.0	12800.0
Controls No-MetS	1185.8	1690.5	2334.0	1964.5	497.0	6299.0	NS
Controls MetS	1389.3	2232.5	2984.5	2358.7	779.0	5659.0
ANGPTL8 (ng/mL)
Patients No-MetS	10.78	13.80	19.00	14.70	5.78	25.50	NS
Patients MetS	10.98	13.92	19.98	14.74	4.60	24.30
Controls No-MetS	10.02	12.20	15.09	12.63	2.30	25.40	NS
Controls MetS	9.47	11.75	15.60	12.98	2.10	32.80
Oxidative damage to nucleic acids (pg/mL)
Patients No-MetS	2004	2931	4506	3415	700	8150	NS
Patients MetS	2270	3517	4523	3651	500	13050
Controls No-MetS	1250	1805	3612	2665	191	16100	NS
Controls MetS	786	1465	2339	1897	128	7800

Legend: Q1: first quartile; Q3: third quartile.